# Darovasertib

Source: https://onco.cc/drugs/darovasertib/  
OnCo record `darovasertib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Darovasertib is an experimental small-molecule drug from IDEAYA Biosciences in phase 3 trials for uveal melanoma and melanoma, with its target not yet stated publicly.

## Summary

Darovasertib (IDE196, LXS196) is a small-molecule drug developed by IDEAYA Biosciences. The sponsor describes its target as PKC (protein kinase C), which OnCo does not yet have a target page for. The sponsor states: Darovasertib is a small-molecule PKC inhibitor targeting the oncogenic driver of uveal melanoma associated with GNAQ/GNA11 mutations or PRKC fusions. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07804186 (Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma) and NCT07015190 (Neoadjuvant Darovasertib in Primary Uveal Melanoma), in uveal melanoma and melanoma. The largest, NCT07015190, plans to enrol 520 participants with primary completion expected 2030-10. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Also known as: IDE 196
- Tags: pipeline; ctgov-ingest
- Code: IDE196, LXS196
- Modality: small molecule
- Mechanism: Darovasertib is a small-molecule PKC inhibitor targeting the oncogenic driver of uveal melanoma associated with GNAQ/GNA11 mutations or PRKC fusions.

## Sources

- ClinicalTrials.gov: trials of Darovasertib: https://clinicaltrials.gov/search?intr=IDE196
- Sponsor pipeline page: https://ideayabio.com/pipeline/

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)
- companies: [IDEAYA Biosciences](https://onco.cc/companies/ideaya-biosciences/)
- trials: [(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma](https://onco.cc/trials/nct05907954/), [IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma](https://onco.cc/trials/nct05987332/), [Neoadjuvant Darovasertib in Primary Uveal Melanoma](https://onco.cc/trials/nct07015190/), [Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma](https://onco.cc/trials/nct07804186/), [Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions](https://onco.cc/trials/nct03947385/)
- targets: [GNA11](https://onco.cc/targets/gna11/), [GNAQ](https://onco.cc/targets/gnaq/)

---
JSON: https://onco.cc/api/v1/entities/darovasertib.json